Changes in the epigenome, such as aberrant DNA methylation and histone modifications are hallmarks of most tumour types, including those of pituitary origin, but are potentially reversible. This Review describes epigenetic changes that can occur in pituitary tumours and discusses some of the therapeutic agents that could be used to target the epigenome for the benefit of patients.
- Kiren Yacqub-Usman
- Alan Richardson
- William E. Farrell